AB0975 LIPID PEROXIDATION AND ANTIOXIDANT PROTECTION IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS ON BIOLOGICAL THERAPY
Authors: I. Chyzheuskaya, L. Byelyaeva, M. Kastsianevich, A. Vishnevskaya, I. Arher, T. Matsushko
Journal: Annals of the Rheumatic Diseases (2020)

Background: Juvenile idiopathic arthritis (JIA) is a chronic immuno-inflammatory joint disease that leads to a child’s disability. Currently, drugs aimed at the main pro-inflammatory cytokines, such as tumor necrosis factor (TNF), interleukin-1 (IL-1), interleukin-6 (IL-6), and others, are successfully used to treat JIA. The effect of these drugs on metabolic processes has been little studied. Objectives: The purpose of the study was to determine the state of lipid peroxidation and antioxidant protection in children with JIA receiving biological therapy. Methods: 28 children with polyarticular JIA, 15 children with systemic JIA and 20 healthy children were examined at the republican center of pediatric rheumatology on the basis of the rheumatology department of the 4th city children’s clinical hospital in Minsk. All patients received methotrexate, non-steroidal anti-inflammatory drugs, and glucocorticoids as needed. Determination of lipid peroxidation (LPO) and serum ACL and ACW were performed at the BelMAPO Central Research Laboratory. Statistical data processing was performed by traditional methods of variation statistics on a personal computer using the Statsoft Statistica 6.0 program. Results: During the study, prior to the use of tocilizumab, results were obtained that indicate the activation of lipid peroxidation processes and the violation of antioxidant defense processes in children with JIA. A significant (P &lt;0.05) increase in the level of lipid peroxidation products in the blood serum of children with JIA compared with healthy children was established: the content of dienconjugates in the blood of children with JIA was 3.12±0.51 opt.pl., in healthy children - 1.65±0.4 units of opt.pl., the content of dienketones in children with JIA - 2.32±4839 units of opt.pl., in healthy children - 0.19±0.08 units of opt.pl., the content of malondialdehyde in children with JIA is 9.14±1.84 μmol/L, in healthy children - 7.13±1.35 μmol/L. A significant (P &lt;0.01) decrease in the serum ACW and ACL in the blood serum of children with JIA was established when compared with the control group: the ACW content in children with JIA was 10.61±5.8 μmol/L, in healthy children - 13, 72±5.24 μmol/L, ACL content in children with JIA - 7.21±2.65 μmol/L, in healthy children - 8.81±3.5 μmol/L. During the treatment with tocilizumab, a remission of the disease was achieved. According to the results of a repeated study of lipid peroxidation and antioxidant protection 6 months after the start of biological therapy, a decrease in LPO activity and an increase in the antioxidant ability of substances in blood serum were found. Thus, the content of dienketones decreased to 1.05±0.17 units of optical density, dienconjugates to 2.4±0.6 units of optical density, and malondialdehyde to 6.3±1.7 μmol/l. The content of ACW increased to 12.91±3.3 μmol/L, and ACL to 8.9±3.5 μmol/L. Conclusion: The results indicate a positive effect of tocilizumab therapy on lipid peroxidation and antioxidant protection in children with JIA. Acknowledgments: This study would not have been possible without the collaboration of numerous Belarusian pediatric rheumatologists, patients and their parents. Disclosure of Interests: None declared